NYC-based TMRW Life Sciences, designs technology that provides safety and transparency to modernize and transform the field of IVF has raised $28 Million Series D Equity Funding round led by 5AM Ventures with participation from FIOS Venture Holdings, DF Investment Partners, Transformation Capital, Life Sciences Innovation Fund, and Casdin Capital.
Read also – [Funding News] Splight Secures $12 Million Seed Funding
Additional support came from leading women’s health investors such as GV (formerly Google Ventures), and actress and advocate Amy Schumer, among others. TMRW created the world’s first and only FDA-cleared, automated platform for the safe management of frozen eggs and embryos.
Read also – [Funding News] Zest Security Raises $5 Million Seed Funding
“5AM Ventures is proud to continue to invest in TMRW to support innovation, growth and expansion. With the use of fertility treatments growing exponentially, the adoption of state-of-the-art specimen management and storage technologies that help reduce risk and improve safety and accuracy for patients has never been more important,” said Andy Schwab, Managing Partner of 5AM Ventures.
“The management and storage of precious cells like sperm, eggs and embryos is too important to leave to antiquated systems developed in the last century,” said Louis Villalba, Chief Executive Officer at TMRW. “We are thrilled to have the continued support of such a distinguished group of investors fast-tracking our mission to transform specimen management and storage and our ability to execute on soaring clinic demand.”
About TMRW Life Sciences
Founded in 2018, TMRW Life Sciences is a fertility technology company that provides safety and transparency to modernize and transform egg and embryo storage. The current system is manual, outdated, and stressful for embryologists and clinicians. Automatization and state-of-the-art technology identify, track and remotely monitor frozen eggs and embryos. TMRW is a scalable solution for overcrowded clinics that have unintentionally become storage facilities since the rise in people seeking fertility treatments.
Named Fast Company’s #1 Most Innovative Biotech Company in 2022, TMRW Life Sciences is in leading clinics across the US and will soon be available in the UK and Europe.
